Johnson & Johnson (JNJ) has entered into a collaboration with Coherus Oncology (CHRS) to supply its bispecific antibody, pasritamig, for a phase 1b trial. This trial will assess the combination of pasritamig with Coherus' monoclonal antibody, tagmokitug, in treating metastatic castration-resistant prostate cancer. Coherus will oversee the trial, and both companies will retain commercial rights to their respective compounds, whether used individually or in combination therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.